The combination of Arcam’s EBM technology and DiSanto´s know-how in orthopedic implant manufacturing will accelerate the market adoption of Additive Manufacturing in the implant industry. DiSanto’s expertise in implant engineering and production of finished components is thus expected to leverage Arcam’s EBM technology for Additive Manufacturing of orthopedic implants.
DiSanto is a fully equipped and certified production facility for the production of finished orthopedic implants with approximately 100 employees. In the last 12 months DiSanto generated approximately USD 12M in revenue and an EBIT of USD 0.6M. The total purchase price amounts to USD 15.8M paid in cash and through the execution of Arcam stock options issued to the sellers in February 2013.
The acquired business will become a subsidiary of Arcam and continue operating with the existing management team. The acquisition is expected to have a positive effect on Arcam’s earnings per share in 2014.
“Through this acquisition Arcam’s offering will cover the entire supply chain for our customers: Metal powders through AP&C, acquired earlier this year, EBM systems and services through Arcam AB and finished products through DiSanto. The acquisition is thus in line with our growth strategy, it complements our technology and product portfolio, and it is immediately accretive. We are very pleased to welcome the skilled DiSanto team to the Arcam group”, says Magnus René, CEO of Arcam.
“With this deal we will be part of the leading company in 3D-printing in metals. This will enable us to help customers in rapidly developing product applications and to commercially produce products for them with Arcam’s cost-efficient, regulatory-cleared Additive Manufacturing technology. Being part of a larger group will also help in accelerating growth to better serve the growing implant market”, says Ronald F. Dunn, President of DiSanto Technology.
Source: Arcam